<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.clinicalmolecularallergy.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Clinical and Molecular Allergy - Latest Articles</title>
        <link>http://www.clinicalmolecularallergy.com</link>
        <description>The latest research articles published by Clinical and Molecular Allergy</description>
        <dc:date>2010-03-15T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/8/1/4" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/8/1/3" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/8/1/2" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/8/1/1" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/7/1/10" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/7/1/9" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/7/1/8" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/7/1/7" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/7/1/6" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/7/1/5" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/8/1/4">
        <title>Lack of neo-sensitization to Pen a 1 in patients treated with mite sublingual immunotherapy</title>
        <description>Background Some studies reported the possible induction of food allergy, caused by neo-sensitization to cross-reacting allergens, during immunotherapy with aeroallergens, while other studies ruled out such possibility.Objectives The aim of this study was to evaluate the development of neo-sensitization to Pen a 1 (tropomyosin) as well as the appearance of reactions after ingestion of foods containing tropomyosin as a consequence of sublingual mite immunization.Material and methods Specific IgE to Tropomyosin (rPen a 1) before and after mite sublingual immunotherapy in 134 subjects were measured. IgE-specific antibodies for mite extract and recombinant allergen Pen a 1 were evaluated using the immunoenzymatic CAP system (Phadia Diagnostics, Milan, Italy).Results All patients had rPen a 1 IgE negative results before and after mite SLIT and did not show positive shrimp extract skin reactivity and serological rPen a 1 IgE conversion after treatment. More important, no patient showed systemic reactions to crustacean ingestion.Conclusions Patients did not show neo-sensitization to tropomyosin, a component of the extract (namely mite group 10) administered. An assessment of a patient&apos;s possible pre-existing sensitisation to tropomyosin by skin test and/or specific IgE prior to start mite extract immunotherapy is recommended.</description>
        <link>http://www.clinicalmolecularallergy.com/content/8/1/4</link>
                <dc:creator>Renato Rossi</dc:creator>
                <dc:creator>Giorgio Monasterolo</dc:creator>
                <dc:creator>Cristoforo Incorvaia</dc:creator>
                <dc:creator>Philippe Moingeon</dc:creator>
                <dc:creator>Franco Frati</dc:creator>
                <dc:creator>Giovanni Passalacqua</dc:creator>
                <dc:creator>Lucilla Rossi</dc:creator>
                <dc:creator>Giorgio Canonica</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2010, 8:4</dc:source>
        <dc:date>2010-03-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-8-4</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2010-03-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/8/1/3">
        <title>Regulation and dysregulation of immunoglobulin E:  a molecular and clinical perspective</title>
        <description>Background:
Altered levels of Immunoglobulin E (IgE) represent a dysregulation of IgE synthesis and may be seen in a variety of immunological disorders. The object of this review is to summarize the historical and molecular aspects of IgE synthesis and the disorders associated with dysregulation of IgE production.
Methods:
Articles published in Medline/PubMed were searched with the keyword Immunoglobulin E and specific terms such as class switch recombination, deficiency and/or specific disease conditions (atopy, neoplasia, renal disease, myeloma, etc.). The selected papers included reviews, case reports, retrospective reviews and molecular mechanisms. Studies involving both sexes and all ages were included in the analysis.
Results:
Both very low and elevated levels of IgE may be seen in clinical practice. Major advancements have been made in our understanding of the molecular basis of IgE class switching including roles for T cells, cytokines and T regulatory (or Treg) cells in this process. Dysregulation of this process may result in either elevated IgE levels or IgE deficiency.
Conclusion:
Evaluation of a patient with elevated IgE must involve a detailed differential diagnosis and consideration of various immunological and non-immunological disorders. The use of appropriate tests will allow the correct diagnosis to be made. This can often assist in the development of tailored treatments.</description>
        <link>http://www.clinicalmolecularallergy.com/content/8/1/3</link>
                <dc:creator>Mariah Pate</dc:creator>
                <dc:creator>John Smith</dc:creator>
                <dc:creator>David Chi</dc:creator>
                <dc:creator>Guha Krishnaswamy</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2010, 8:3</dc:source>
        <dc:date>2010-02-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-8-3</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2010-02-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/8/1/2">
        <title>Basophil sensitivity through CD63 or CD203c is a functional measure for specific immunotherapy </title>
        <description>Background:
Subcutaneous Immunotherapy (SCIT) modifies the allergic response and relieves allergic symptoms. SCIT is the only and a very effective treatment for insect venom allergy. We hypothesized that basophil sensitivity, measured through the basophil activation test, would decrease during SCIT up dosing. Expression of CD203c was compared to CD63 as marker for basophil activation, using a Bland Altman plot and ROC curves.
Methods:
Patients (n = 18) starting subcutaneous SCIT for wasp allergy with an up dosing scheme of 7 to 11 weeks were enrolled. Heparinised blood samples were drawn at weeks 1-4, 7 and at the first maintenance visit. Basophils were stimulated at 7 log dilutions of V. vespula allergen for 15 min, and were stained with CD203c and CD63. Basophils were identified as CD203c+ leukocytes, and the proportion of CD63+ and CD203c+ cells were plotted against allergen concentration. A sigmoid curve was fitted to the points, and the allergen concentration at which half of the maximal activation was achieved, LC50, was calculated. In another series of experiments, LC50 calculated in whole blood (AP) was subtracted from LC50 calculated with basophils suspended in plasma from a nonatopic donor (HS) to determine the protective effect of soluble factors in blood of patients treated with SCIT.
Results:
Heparin blood basophil activation was similar through CD63 and CD203c. Basophils were significantly more sensitized three weeks after initiation of SCIT compared to baseline (p &lt; 0,01). The difference in LC50 increased by 1,04 LC50 units (p = 0,04) in patients that had just achieved maintenance dose compared with patients before initiating SCIT. When maintenance allergen concentrations had been reached, an increase in the protective plasma component was documented. Blood basophil concentration was marginally reduced by SCIT.
Conclusion:
Basophil activation is a versatile and sensitive tool that measures changes in the humoral immune response to allergen during SCIT.</description>
        <link>http://www.clinicalmolecularallergy.com/content/8/1/2</link>
                <dc:creator>Susan Mikkelsen</dc:creator>
                <dc:creator>Bo Martin Bibby</dc:creator>
                <dc:creator>Mette Konow Bogebjerg Dolberg</dc:creator>
                <dc:creator>Ronald Dahl</dc:creator>
                <dc:creator>Hans Jurgen Hoffmann</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2010, 8:2</dc:source>
        <dc:date>2010-02-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-8-2</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2010-02-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/8/1/1">
        <title>Non-allergic rhinitis: a case report and review</title>
        <description>Rhinitis is characterized by rhinorrhea, sneezing, nasal congestion, nasal itch and/or postnasal drip. Often the first step in arriving at a diagnosis is to exclude or diagnose sensitivity to inhalant allergens. Non-allergic rhinitis (NAR) comprises multiple distinct conditions that may even co-exist with allergic rhinitis (AR). They may differ in their presentation and treatment. As well, the pathogenesis of NAR is not clearly elucidated and likely varied. There are many conditions that can have similar presentations to NAR or AR, including nasal polyps, anatomical/mechanical factors, autoimmune diseases, metabolic conditions, genetic conditions and immunodeficiency. Here we present a case of a rare condition initially diagnosed and treated as typical allergic rhinitis vs. vasomotor rhinitis, but found to be something much more serious. This case illustrates the importance of maintaining an appropriate differential diagnosis for a complaint routinely seen as mundane. The case presentation is followed by a review of the potential causes and pathogenesis of NAR.</description>
        <link>http://www.clinicalmolecularallergy.com/content/8/1/1</link>
                <dc:creator>Cyrus Nozad</dc:creator>
                <dc:creator>L. Madison Michael</dc:creator>
                <dc:creator>D. Betty Lew</dc:creator>
                <dc:creator>Christie Michael</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2010, 8:1</dc:source>
        <dc:date>2010-02-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-8-1</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2010-02-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/7/1/10">
        <title>Oral mite anaphylaxis by Thyreophagus entomophagus in a child: a case report</title>
        <description>Sensitization to Thyreophagus entomophagus, a storage mite, is uncommon and might produce occupational respiratory disorders in farmers. We present the first case of a child suffering anaphylaxis produced by ingestion of contaminated flour with Thyreophagus entomophagus.</description>
        <link>http://www.clinicalmolecularallergy.com/content/7/1/10</link>
                <dc:creator>Javier Iglesias-Souto</dc:creator>
                <dc:creator>Inmaculada Sanchez-Machin</dc:creator>
                <dc:creator>Victor Iraola</dc:creator>
                <dc:creator>Paloma Poza</dc:creator>
                <dc:creator>Ruperto Gonzalez</dc:creator>
                <dc:creator>Victor Matheu</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2009, 7:10</dc:source>
        <dc:date>2009-11-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-7-10</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2009-11-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/7/1/9">
        <title>Value of eight-amino-acid matches in predicting the allergenicity status of proteins: an empirical bioinformatic investigation </title>
        <description>The use of biotechnological techniques to introduce novel proteins into food crops (transgenic or GM crops) has motivated investigation into the properties of proteins that favor their potential to elicit allergic reactions. As part of the allergenicity assessment, bioinformatic approaches are used to compare the amino-acid sequence of candidate proteins with sequences in a database of known allergens to predict potential cross reactivity between novel food proteins and proteins to which people have become sensitized. Two criteria commonly used for these queries are searches over 80-amino-acid stretches for &gt;35% identity, and searches for 8-amino-acid contiguous matches. We investigated the added value provided by the 8-amino-acid criterion over that provided by the &gt;35%-identity-over-80-amino-acid criterion, by identifying allergens pairs that only met the former criterion, but not the latter criterion. We found that the allergen-sequence pairs only sharing 8-amino-acid identity, but not &gt;35% identity over 80 amino acids, were unlikely to be cross reactive allergens. Thus, the common search for 8-amino-acid identity between novel proteins and known allergens appears to be of little additional value in assessing the potential allergenicity of novel proteins.</description>
        <link>http://www.clinicalmolecularallergy.com/content/7/1/9</link>
                <dc:creator>Rod Herman</dc:creator>
                <dc:creator>Ping Song</dc:creator>
                <dc:creator>Arvind ThirumalaiswamySekhar</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2009, 7:9</dc:source>
        <dc:date>2009-10-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-7-9</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2009-10-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/7/1/8">
        <title>Characterization of Regulatory T cells in Urban Newborns </title>
        <description>Background:
In the United States, asthma prevalence is particularly high among urban children. Although the underlying immune mechanism contributing to asthma has not been identified, having impaired T regulatory (Treg) cells at birth may be a determining factor in urban children. The objective of this study was to compare Treg phenotype and function in cord blood (CB) of newborns to those in peripheral blood (PB) of a subset of participating mothers.
Methods:
Treg numbers, expression, and suppressive function were quantified in subjects recruited prenatally from neighborhoods where &#8805; 20% of families have incomes below the poverty line. Proportion of Treg cells and expression of na&#239;ve (CD45RA) or activated (CD45RO, CD69, and HLA-DR) markers in CD4+T cells was measured by flow cytometry. Treg suppressive capacity was determined by quantifying PHA-stimulated lymphocyte proliferation in mononuclear cell samples with and without CD25 depletion.
Results:
In an urban cohort of 119 newborns and 82 mothers, we found that newborns had similar number of cells expressing FOXP3 as compared to the mothers but had reduced numbers of CD4+CD25+bright cells that predominantly expressed the na&#239;ve (CD45RA) rather than the activated/memory (CD45RO) phenotype found in the mothers. Additionally, the newborns had reduced mononuclear cell TGF-&#946; production, and reduced Treg suppression of PHA-stimulated lymphocyte proliferation compared to the mothers.
Conclusion:
U.S. urban newborns have Treg cells that express FOXP3, albeit with an immature phenotype and function as compared to the mothers. Longitudinal follow-up is needed to delineate Treg cell maturation and subsequent risk for atopic diseases in this urban birth cohort.</description>
        <link>http://www.clinicalmolecularallergy.com/content/7/1/8</link>
                <dc:creator>Ngoc Ly</dc:creator>
                <dc:creator>Begona Ruiz-Perez</dc:creator>
                <dc:creator>Rachel McLoughlin</dc:creator>
                <dc:creator>Cynthia Visness</dc:creator>
                <dc:creator>Paul Wallace</dc:creator>
                <dc:creator>William Cruikshank</dc:creator>
                <dc:creator>Authur Tzianabos</dc:creator>
                <dc:creator>George O'Connor</dc:creator>
                <dc:creator>Diane Gold</dc:creator>
                <dc:creator>James Gern</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2009, 7:8</dc:source>
        <dc:date>2009-07-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-7-8</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2009-07-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/7/1/7">
        <title>Genetics of asthma: a molecular biologist perspective

</title>
        <description>Asthma belongs to the category of classical allergic diseases which generally arise due to IgE mediated hypersensitivity to environmental triggers. Since its prevalence is very high in developed or urbanized societies it is also referred to as &quot;disease of civilizations&quot;. Due to its increased prevalence among related individuals, it was understood quite long back that it is a genetic disorder. Well designed epidemiological studies reinforced these views. The advent of modern biological technology saw further refinements in our understanding of genetics of asthma and led to the realization that asthma is not a disorder with simple Mendelian mode of inheritance but a multifactorial disorder of the airways brought about by complex interaction between genetic and environmental factors. Current asthma research has witnessed evidences that are compelling researchers to redefine asthma altogether. Although no consensus exists among workers regarding its definition, it seems obvious that several pathologies, all affecting the airways, have been clubbed into one common category called asthma. Needless to say, genetic studies have led from the front in bringing about these transformations. Genomics, molecular biology, immunology and other interrelated disciplines have unearthed data that has changed the way we think about asthma now. In this review, we center our discussions on genetic basis of asthma; the molecular mechanisms involved in its pathogenesis. Taking cue from the existing data we would briefly ponder over the future directions that should improve our understanding of asthma pathogenesis.</description>
        <link>http://www.clinicalmolecularallergy.com/content/7/1/7</link>
                <dc:creator>Amrendra Kumar</dc:creator>
                <dc:creator>Balaram Ghosh</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2009, 7:7</dc:source>
        <dc:date>2009-05-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-7-7</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2009-05-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/7/1/6">
        <title>An extract of the medicinal mushroom Agaricus blazei Murill can protect against allergy</title>
        <description>Background:
Agaricus blazei Murill (AbM) is an edible Brazilian mushroom that has been used in traditional medicine for a range of diseases. It has been shown to have anti-infection and anti-tumor properties in the mouse, which are due to induction of Th1 responses. On the other hand, IgE-mediated allergy is induced by a Th2 response.ObjectiveSince according to the Th1/Th2 paradigm an increased Th1 response may promote a reduced Th2 response, the aim was to examine whether AbM had anti-allergy effects.
Methods:
A mouse model for allergy was employed, in which the mice were immunized s.c. with the model allergen ovalbumin (OVA). Additionally, the animals were given a mushroom extract, AndoSan&#8482;, mainly (82%) containing AbM, but also Hericium erinaceum (15%) and Grifola frondosa (3%), or PBS p.o. either a day before or 19 days after the immunization. The mice were sacrificed on day 26, and anti-OVA IgE (Th2 response) and IgG2a (Th1 response) antibodies were examined in serum and Th1, Th2 and Treg cytokines in spleen cells cultures.
Results:
It was found that the AndoSan&#8482; extract both when given either before or after OVA immunization reduced the levels of anti-OVA IgE, but not IgG2a, in the mice. There was a tendency to reduced Th2 relative to Th1 cytokine levels in the AndoSan&#8482; groups.
Conclusion:
This particular AbM extract may both prevent allergy development and be used as a therapeutical substance against established allergy.</description>
        <link>http://www.clinicalmolecularallergy.com/content/7/1/6</link>
                <dc:creator>Linda Ellertsen</dc:creator>
                <dc:creator>Geir Hetland</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2009, 7:6</dc:source>
        <dc:date>2009-05-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-7-6</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2009-05-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/7/1/5">
        <title>T regulatory cells: an overview and intervention techniques to modulate allergy outcome</title>
        <description>Dysregulated immune response results in inflammatory symptoms in the respiratory mucosa leading to asthma and allergy in susceptible individuals. The T helper type 2 (Th2) subsets are primarily involved in this disease process. Nevertheless, there is growing evidence in support of T cells with regulatory potential that operates in non-allergic individuals. These regulatory T cells occur naturally are called natural T regulatory cells (nTregs) and express the transcription factor Foxp3. They are selected in the thymus and move to the periphery. The CD4 Th cells in the periphery can be induced to become regulatory T cells and hence called induced or adaptive T regulatory cells. These cells can make IL-10 or TGF-b or both, by which they attain most of their suppressive activity. This review gives an overview of the regulatory T cells, their role in allergic diseases and explores possible interventionist approaches to manipulate Tregs for achieving therapeutic goals.</description>
        <link>http://www.clinicalmolecularallergy.com/content/7/1/5</link>
                <dc:creator>Subhadra Nandakumar</dc:creator>
                <dc:creator>Christopher Miller</dc:creator>
                <dc:creator>Uday Kumaraguru</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2009, 7:5</dc:source>
        <dc:date>2009-03-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-7-5</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2009-03-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
